CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci  by Mu, Yanshuang et al.
FEBS Letters 589 (2015) 849–856journal homepage: www.FEBSLetters .orgCHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized
at the transthyretin and retinol-binding protein lociqhttp://dx.doi.org/10.1016/j.febslet.2015.02.020
0014-5793/ 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Abbreviations: CHF5074, [1-(30 ,40-dichloro-2-ﬂuoro[1,10-biphenyl]-4-yl)-cyclo-
propane carboxylic acid]; RBP, retinol binding protein; T4, thyroxin; TTR,
transthyretin
q Author contributions: Z.L. and K.Y. conceived and designed the experiments;
Y.M., S.J., J.S., L.Q. and Z.L. performed the experiments; A.S. and Y.T. analyzed the
data; and Z.L., B.P.I. and K.Y. wrote the paper.
⇑ Corresponding author at: Department of Histology and Embryology, Harbin
Medical University, 194 Xuefu Road, Nangang District, Harbin 150081, China. Fax:
+86 451 86674518, +81 96 373 6596.
E-mail address: liseika@kumamoto-u.ac.jp (Z. Li).
1 These authors contributed equally.Yanshuang Mub,c,1, Shoude Jin d,1, Jingling Shen a, Aki Sugano e, Yutaka Takaoka e, Lixia Qiang b,
Bruno P. Imbimbo f, Ken-ichi Yamamura b, Zhenghua Li a,b,⇑
aDepartment of Histology and Embryology, Harbin Medical University, Harbin, China
b Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan
cCollege of Life Sciences, Northeast Agriculture University, Harbin, China
dDivision of Respiratory Disease, The Fourth Afﬁliated Hospital of Harbin Medical University, Harbin, China
eDivision of Medical Informatics and Bioinformatics, Kobe University Hospital, Kobe, Japan
fResearch and Development, Chiesi Farmaceutici, Parma, Italy
a r t i c l e i n f o a b s t r a c tArticle history:
Received 9 December 2014
Revised 12 February 2015
Accepted 17 February 2015
Available online 26 February 2015
Edited by Jesus Avila
Keywords:
CHF5074 (CSP-1103)
Familial amyloidotic polyneuropathy
Misfolding
Retinol binding protein
TransthyretinFamilial amyloidotic polyneuropathy is one type of protein misfolding disease. Transthyretin (TTR)
tetramer dissociation is the limiting step for amyloid ﬁbril formation. CHF5074 (CSP-1103) stabilizes
TTR tetramer in vitro by binding to the T4 binding site. Here, we used three strains of double human-
ized mice (mTtrhTTRVal30/hTTRVal30, mTtrhTTRVal30/hTTRMet30, and mTtrhTTRMet30/hTTRMet30) to assess
whether CHF5074 stabilizes TTR tetramers in vivo. Treatment of mice with CHF5074 increased serum
TTR levels by stabilizing TTR tetramers. Although the binding afﬁnities of CHF5074 and diﬂunisal
with TTRMet30 were similar, CHF5074 bound TTRVal30 more strongly than did diﬂunisal, suggesting
the potent TTR-stabilizing activity of CHF5074.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Structural studies of the TTR tetramer have disclosed severalFamilial amyloidotic polyneuropathy is an autosomal dominant
disorder caused by a point mutation in the transthyretin (TTR)
gene. TTR is a 127-amino acid, 55-kDa homotetrameric protein
that circulates as a tetramer composed of four identical, non-cova-
lently associated subunits [1,2]. TTR serves as a transport molecule
for thyroxine (T4) and retinol binding protein (RBP). The process of
TTR amyloidogenesis involves rate-limiting dissociation of TTR tet-
ramer, followed by partial unfolding of monomers to yield non-ﬁb-
rillar aggregates, protoﬁbrils, and mature amyloid ﬁbrils [3–5].negatively cooperative compounds that bind to the T4 hormone
pocket of TTR, consequently stabilizing the soluble form of TTR
and inhibiting ﬁbril formation [6–9].
CHF5074 (CSP-1103) [1-(30,40-dichloro-2-ﬂuoro[1,10-biphenyl]-
4-yl)-cyclopropane carboxylic acid] is a non-steroidal anti-inﬂam-
matory derivative that lacks cyclooxygenase inhibitory activity.
CHF5074 stimulates the phagocytic activity of microglia [10] and
inhibits b-amyloid plaque deposition in the brains of various trans-
genic mouse models of Alzheimer disease [11–15]. X-ray analysis
of the TTR crystal structure recently revealed that CHF5074 binds
to the T4 sites of TTR tetramer and prevents acidic pH-induced
TTR dissociation in vitro [16].
To assess the in vivo efﬁcacy of drug candidates, animal models
that reproduce the pathology of human TTR-mediated familial
amyloidosis are required. By using a Cre-mediated recombination
system, we previously produced humanized mice carrying either
human normal (Val30) or mutant (Met30) TTR cDNA at the mouse
Ttr locus [17]. By using the same strategy, we also created a
humanized mouse carrying the human RBP gene at the mouse
Rbp locus (manuscript, submitted). We then crossed these two
lines to generate mice humanized at both the Ttr locus and the
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would be better to humanize not only TTR but its binding mole-
cules to mimic the physiological condition of human serum fur-
ther. We therefore crossed these two lines to generate mice
humanized at both the Ttr locus and the Rbp locus in which human
TTR binds with human RBP4.
Here, we examined the short-term effect of oral CHF5074
administration on hTTR tetramer stabilization in mice humanized
for both TTR and RBP. The data showed that CHF5074 stabilized
TTR tetramers to increase serum levels of hVal30 and hMet30, sug-
gesting that CHF5074 is a viable candidate inhibitor of TTR
amyloid.2. Materials and methods
2.1. Animals and CHF5074 treatment
All animal experiments were performed in accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the US National Institutes of Health. The mouse lines
carrying either normal human TTR (hVal30) (mTtrhTTRVal30/
hTTRVal30) or mutant human TTR (hMet30) (mTtrhTTRMet30/hTTRMet30)
at the mouse Ttr locus (humanized TTR mice) have been described
previously [17]. Mouse lines with human Rbp4 at the mouse Rbp4
locus (mRbp4hRBP4) (humanized Rbp4 mice) were produced in a
similar way to the hTTR mice (manuscript in submission).
We used three mouse strains, mTtrhTTRVal30/hTTRVal30:-
mRbp4
hRBP4/hRBP4
(hVal30:hRBP4), mTtrhTTRVal30/hTTRMet30:mRbp4hRBP4/
hRBP4 (hVal30/Met30:hRBP4), and mTtrhTTRMet30/hTTRMet30:-
mRbp4
hRBP4/hRBP4
(hMet30:hRBP4). Beginning at 13 weeks of age, mice
were fed a CHF5074-containing diet (375 ppm, corresponding to
about 60 lc/kg/day). To analyze hepatic mRNA expression of the
TTR or hRBP4 gene, liver samples for RNA isolation were obtained
after 0, 3, 7, and 14 days of CHF5074 feeding. To evaluate serum
hTTR and hRBP4 levels, blood samples were collected from the
retro-orbital sinus at 0, 3, 7, 14, 21 and 28 days. To assess the sta-
bility of hTTR, blood samples were obtained at 0, 3, 7 and 14 days.
2.2. Semi-quantitative RT-PCR analyses
Semi-quantitative RT-PCR analyses were performed as
described previously [18]. To assess hTTR mRNA expression, we
used the primers mhTTR-F1 (sense, 50-GTCCTCTGATGGTCAAAG
T-30) and mhTTR-R2 (anti-sense, 50-GAGTCGTTGGCTGTGAA-30).
For evaluation of hRBP4 mRNA, we used mhRBP4-F (sense,
50-GAG TCA AGG AGA ACT TCG AC-30) and mhRBP4-e4R (antisense,
50-CAG TAC TTC ATC TTG AAC TTG G-30). The primers used for
detection of mRNA from the housekeeping gene Hprt were
50-CAC AGG ACT AGA ACA CCT GC-30 (sense) and 50-GCT GGT
GAA AAG GAC CTC T-30 (antisense). Ampliﬁed PCR products were
separated by 1.5% agarose gel electrophoresis and visualized by
ethidium bromide staining.
2.3. Serum hTTR and hRBP4 levels
Commercial ELISA kits were used according to the manufactur-
ers’ instructions to determine serum concentrations of hTTR
(KA0495, Abnova, Taipei, China) and hRBP4 (AG-45A-0035, Adipo-
Gen, San Diego, CA, USA).
2.4. Evaluation of serum TTR tetramer stability against acid- or urea-
mediated denaturation
Dissociation of TTR tetramers and unfolding of monomers are
accelerated under acidic or high-urea conditions [3,4]. Therefore,we used acid- or urea-mediated denaturation to discern the sta-
bility of hTTR in the sera of these mice. The extent of denaturation
of hTTR from mice fed either the CHF5074-containing or control
diet can be assessed by evaluating how much folded tetramer
remains.
Blood samples were processed according to methods described
elsewhere [19,20]. Acid- or urea-treated samples subsequently
underwent gradient (10–20%) denaturing polyacrylamide gel elec-
trophoresis. Separated proteins were transferred onto polyvinyli-
dene diﬂuoride membranes (BioRad Laboratories, Hercules, CA,
USA) and then reacted with a polyclonal anti-TTR primary antibody
(1:500) (Sigma, St. Louis, MO, USA) and a horseradish-peroxidase–
conjugated secondary antibody (1:2500) (GE Healthcare,
Dornstadt, Germany). The blotted proteins were quantiﬁed by
using ECL Western Blotting Detection Reagents (GE Healthcare).
2.5. Statistical analysis of serum hTTR stability
To quantify the stability of serum hTTR tetramers, the densities
of all TTR bands were quantiﬁed by using ImageJ software (version
1.48v, http://rsb.info.nih.gov/ij/docs/index.html). hTTR stability
was evaluated according to the percentage of tetrameric hTTR or
folded TTR (tetramers, trimers, and dimers) remaining by using
the following formulas:
% tetramer at time t¼100%ðtetramer density at pH 4:0;time tÞ
=ðtetramer density at pH7; time 0Þ
% tetramer at time t¼100%ðtetramerdensity at 6Murea;time tÞ
=ðtetramerdensity at 0Murea; time 0Þ
% folded TTR at time t ¼ 100% ðfolded TTR at pH 7:0; time tÞ
=ðfolded TTR at pH 7:0; time 0Þ
Results are expressed as means ± standard error of the mean.
The percentages of tetrameric TTR of different hTTR variants from
mice with and without drug treatment were compared by using
t-tests. Differences were considered statistically signiﬁcant at
P < 0.05.
2.6. 3-D structures of the TTR tetramer
The 3-D structure of wild-type human TTR tetrameric complex
was downloaded from the Protein Data Bank (PDB ID: 1rlb). The
3-D structure of the hMet30 mutant was constructed by creating
a Val30Met substitution in wild-type hTTR. Then we subjected
the structure of the hMet30 tetramer to molecular mechanics cal-
culations by using MOE software (version 2011.10, Chemical Com-
puting Group, Montreal, Quebec, Canada) with the AMBER99 force
ﬁeld and the generalized Born solvation model until the root mean
square gradient was 0.01 kcal mol1 Å1. This was followed by
5-ns molecular dynamics simulations at 310 K.
2.7. Docking simulation of TTR and CHF5074
We performed 100 docking runs of CHF5074 and hVal30 or
hMet30 tetramers by using MOE Dock (Chemical Computing
Group). The 3-D structure of CHF5074 was downloaded from Che-
mIDPlus (registry number, 749269-83-8). The docking sites of
CHF5074 were determined as the T4 binding site (PDB ID: 1ict).
Because the hTTR tetramer has two T4 binding sites, one or two
ligand molecules were bound to each TTR tetramer. The complex
comprising hVal30 or hMet30 tetramer and one or two molecules
of CHF5074 that had the lowest S score was selected and subjected
to molecular mechanics calculation by using MOE software with
the OPLS-AA force ﬁeld and the generalized Born solvation model
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followed by 5-ns molecular dynamics simulations at 310 K. The
interaction energies between CHF5074 and the four hTTR subunits
were calculated by using the potential energy function in the MOE
software.
3. Results
Oral CHF5074 was well tolerated by all mice; no obvious side
effects were observed during or after the study, according to body
weight and the results of physical examination, blood biochemistry
and hematology analyses.
3.1. Effects of CHF5074 on serum hTTR levels
Before CHF5074 treatment, the serum level of hVal30 (wild-
type) in hVal30:hRBP4 mice was 4.04 ± 0.15 lg/mL, and that of
hMet30 (mutant) in hMet30:hRBP4 mice was 0.56 ± 0.14 lg/mL.
Given that hepatic TTR mRNA expression was similar in
hVal30:hRBP4 and hMet30:hRBP4 mice, the low serum level of
hMet30 likely was due to the instability of hMet30 tetramers in
the serum. In hVal30:hRBP4 mice, the serum level of hVal30 was
increased 3 days after the start of the CHF5074 diet compared withFig. 1. Effect of CHF5074 on serum concentrations of TTR tetramers. (A) Serum hTTR leve
average after CHF5074 treatment. (B) Serum Val30 tetramer levels in hVal30:hRBP4 mice
treatment. (C) Serum hTTR levels in hMet30:hRBP4 mice. Serum hMet30 levels increase
levels in hMet30:hRBP4 mice. Serum hMet30 levels increased approximately 2.0, 5.8, a
⁄P < 0.05; ⁄⁄P < 0.01.pretreatment concentrations and remained at similar levels
(5.10–6.12 lg/mL) thereafter. The maximal level of serum hVal30
was about 1.5 times that before treatment (Fig. 1A). To assess
whether the increase in serum TTR concentrations was due to an
increase in the amount of hVal30 tetramer, we used Western blot
analysis to determine the level of tetramer. The amount of hVal30
tetramer in the serum was increased 3 days after the start of the
CHF5074 diet and remained at similar levels (1.46–1.55 times
the pretreatment level) thereafter (Fig. 1B).
In hMet30:hRBP4 mice, the serum concentration of hTTR was
increased 3 days after the start of the CHF5074 diet and remained
at similar levels (1.73–2.68 lg/mL) thereafter. The maximal level of
serum hMet30 was about 5 times that before treatment but was
only 30–40% that of hVal30 in Val30:hRBP4 mice (Fig. 1B). As seen
for hVal30 tetramer, this increase was due to an increase in
hMet30 tetramers. The amount of hMet30 tetramer in the serum
was increased to 2.03, 5.77, and 5.63 times the pretreatment level
at 3, 7, and 14 days, respectively, after the start of the CHF5074 diet
(Fig. 1D). Furthermore, levels of trimers and dimers were increased
in addition to those of tetramers (Fig. 1B and D), suggesting that
CHF5074 can bind to TTR trimers and dimers. These results suggest
that the increased levels of serum hVal30 and hMet30 were due to
stabilization of tetramers after the binding of CHF5074 and that thels in hVal30:hRBP4 mice. Serum hVal30 levels increased approximately 1.4 times on
. Serum hVal30 levels increased approximately 1.5 times on average after CHF5074
d about 3.7 times on average after CHF5074 treatment. (D) Serum Met30 tetramer
nd 5.6 times at 3, 7, and 14 days, respectively, after the start of the CHF5074 diet.
Fig. 2. Effect of CHF5074 on serum concentrations of RBP4. (A) Serum hRBP4 levels
in hVal30:hRBP4 mice. Serum hRBP4 levels before and after CHF5074 treatment did
not differ. (B) Serum hRBP4 levels in hMet30:hRBP4 mice. Serum hRBP4 levels
before and after CHF5074 treatment did not differ. ⁄⁄P < 0.01.
852 Y. Mu et al. / FEBS Letters 589 (2015) 849–856stabilization effect of CHF5074 was more intense in hMet30:RBP4
than in hVal30:hRBP4 mice.
3.2. Effects of CHF5074 on serum hRBP4 levels
Serum levels of hRBP4 did not change in either hVal30:hRBP4 or
hMet30:hRBP4 mice after provision of the CHF5074-containing
diet (Fig. 2).Fig. 3. Effect of CHF5074 on hepatic levels of hTTR and hRBP4 mRNA. (A) RT-PCR
hMet30:hRBP4 mice. Total RNA isolated from liver samples was harvested on day 0 and o
to semi-quantitative RT-PCR analysis. hTTR and hRBP4 mRNA expression levels did not3.3. Effects of CHF5074 on hepatic expression of hTTR and hRBP4
mRNAs
To analyze whether the increased serum TTR concentrations
after CHF5074 supplementation were due to increased TTR tran-
scription, we examined the levels of hTTR mRNA in liver. Quanti-
ties of hVal30 or hMet30 mRNA in hVal30:hRBP4 or hMet30:
hRBP4 mice did not change after provision of the CHF5074 diet
(Fig. 3). These results suggested that CHF5074 did not affect hepat-
ic hTTR mRNA expression. In addition, the amounts of hRBP4 in
hVal30:hRBP4 and hMet30:hRBP4 mice did not change after provi-
sion of the CHF5074 diet (Fig. 3).
3.4. CHF5074 stabilizes serum hTTR under acidic conditions
We analyzed the CHF5074-associated kinetic stabilization of
hTTR under denaturation stress. As described before, the effect of
a diet containing CHF5074 for 28 days on the extent of denatura-
tion of hTTR tetramer can be assessed by evaluating howmuch tet-
ramer or folded TTR (tetramers, trimers, and dimers) remains.
The denaturation of hTTR tetramers under low pH conditions at
37 C was monitored by Western blot. First, the stability of hVal30
homotetramers from mice given or not given dietary CHF5074 was
assessed after exposing the serum samples to various pH (3.6–7.0)
conditions for 3 days. The percentage of folded TTR (hVal30) was
clearly higher in the presence of CHF5074 than in its absence at
every pH condition tested (Fig. 4A). Because the folded TTR was
dissociated almost completely at pH 4.0 in the absence of
CHF5074, we used this pH condition in the following experiments.
The percentages of native hTTR tetramer (means ± standard
error) from hVal30:hRBP4 and hVal30/hMet30:hRBP4 mice with-
out CHF5074 treatment were lower than those from mice with
CHF5074 treatment after denaturation stress at pH 4.0 for 24, 48,
or 72 h (Fig. 4B). For hMet30:hRBP4 mice, the percentage of native
tetramer in the absence of CHF5074 was lower than that withof mRNA isolated from hVal30:hRBP4 mice. (B) RT-PCR of mRNA isolated from
n days 3, 7, and 14 after initiation of the CHF5074-containing diet and was subjected
differ between any time points.
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results suggest that CHF5074 effectively stabilized hVal30 homote-
tramers and hVal30–hMet30 heterotetramers but that hMet30
homotetramers were more unstable than were the other tetra-
mers, even in the presence of CHF5074. Therefore, the denatura-
tion stress associated with pH 4.0 conditions may be too strong
for hMet30 homotetramers to withstand, even in the presence of
CHF5074.
3.5. CHF5074 stabilizes serum hTTR under urea denaturation
conditions
To determine the optimal concentration of urea at which to test
the stability of hTTR tetramers, serum samples from hVal30:hRBP4
mice before and after CHF5074 feeding were incubated in various
concentrations of urea (0–10 M) for 3 days. The folded TTR
(hVal30) was clearly more stable in the presence of CHF5074 than
in its absence at every urea concentration tested (Fig. 5A). When
6 M urea was used, the percentage of folded TTR after CHF5074
feeding was clearly higher than that in the absence of CHF5074;
we therefore used that denaturation condition in the following
experiments.
After denaturation stress with 6 M urea, the percentage of
native hTTR tetramer from hVal30:hRBP4 mice fed the control diet
was lower than that in mice fed the CHF5074 diet at the 24-, 48-,
and 72-h time points (Fig. 5B). The percentage of native hTTR tet-
ramer in hVal30/hMet30:hRBP4 mice was lower in the absence ofFig. 4. Resistance to acid-mediated denaturation of serum hTTR from mice fed the CHF
denaturation (72 h) under various pH conditions. The folded TTR dissociated almost c
denaturation (pH 4.0) of serum hTTR with or without CHF5074. Three types of te
homotetramers) were stabilized after CHF5074 supplementation of mice. ⁄P < 0.05; ⁄⁄P <CHF5074 than with CHF5074 after urea denaturation for 12, 24, 48,
or 72 h (Fig. 5B). In hMet30:hRBP4 mice, the percentage of native
hTTR tetramer without CHF5074 was lower than that after
CHF5074 at the 24-, 48-, and 72-h time points for urea exposure
(Fig. 5B). These results are similar in pattern to those after expo-
sure to acidic pH, again suggesting that CHF5074 effectively stabi-
lizes TTR tetramers.
3.6. Computational studies of binding afﬁnity of CHF5074 with TTR
tetramer
Diﬂunisal is a well-characterized inhibitor of ﬁbrillogenesis
[21]. Although the mode of binding to the T4 sites of TTR differs
between CHF5074 and diﬂunisal, these two ﬁbrillogenesis inhibi-
tors exhibit similar stabilizing effects on TTR structure [16]. We
therefore used computational docking simulation analysis to study
the binding afﬁnity between TTR and CHF5074 or diﬂunisal.
The structures of T4 and CHF5074 (Fig. 6A) are similar, as are
their modes of binding to TTR (Fig. 6B). The binding afﬁnity of
CHF5074 for hMet30 was similar to that of diﬂunisal, whereas
CHF5074 bound hVal30 with much greater afﬁnity than did diﬂu-
nisal (Table 1).
4. Discussion
We demonstrated that CHF5074 stabilized both normal and
mutant TTR tetramers against denaturing stresses due to both acid5074-containing or control diet. (A) Serum hTTR with and without CHF5074 after
ompletely at pH 4.0 in the absence of CHF5074. (B) Time course of acid-induced
tramers (hVal30 homotetramers, hVal30–hMet30 heterotetramers, and hMet30
0.01.
Fig. 5. Resistance to urea-mediated denaturation of serum hTTR frommice fed the CHF5074-containing or control diet. (A) Time course of urea-induced denaturation (6 M) of
serum hTTR with or without CHF5074. Serum hTTR with and without CHF5074 after denaturation (72 h) at various concentrations of urea. At 6 M urea, the percentage of
folded TTR after CHF5074 feeding was clearly higher than that in the absence of CHF5074. (B) Quantitative analysis of serum hTTR stability. Two types of tetramers (hVal30
homotetramers and hVal30–hMet30 heterotetramers) were stabilized after CHF5074 supplementation of mice. ⁄P < 0.05; ⁄⁄P < 0.01.
Fig. 6. Computational studies of binding afﬁnity of CHF5074 for TTR tetramer (A) Structural diagram of TTR ligands. Carbon, green; hydrogen, white; nitrogen, blue; iodide,
purple; oxygen, red; chloride, gray; ﬂuoride, light blue. B. Proposed structure of hTTR in complex with CHF5074 at pH 7.0. The ribbon diagram of tetrameric TTR with bound
ligand within the two T4 binding pockets, at the weak dimer–dimer interface, is shown. The close-up view depicts TTR within a single binding site. Green, CHF5074; purple,
T4.
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Table 1
Computational studies of binding afﬁnity.
ZDOCK score
(kcal/molecule)
CHF5074 Diﬂunisal
One molecule binding Two molecule binding One molecule binding Two molecule binding
Binding between
A and C
Binding between
B and D
Binding between A and C Binding between B and D
TTRVal30 A 24.0 16.7 18.5 12.1
B 14.0 23.6 10.9 4.0
C 14.3 26.1 9.3 19.8
D 25.1 19.7 7.9 10.0
Total 38.3 39.0 86.1 27.8 18.8 45.9
TTR Met30 A 24.6 26.1 18.5 13.0
B 14.6 13.6 15.5 20.1
C 14.8 8.1 9.4 15.6
D 14.2 21.5 6.6 17.7
Total 39.4 28.8 69.3 27.9 22.1 66.4
Potential energy was expressed as kcal/mol. There was a signiﬁcant difference in the potential energy between TTRVal30-CHF5074 and TTRVal30-diﬂunisal.
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CHF5074-containing diet. These data are consistent with the
results we obtained from computational studies of binding afﬁni-
ty.hVal30 (that is, wild-type) levels in the sera of our humanized
mice were about 1/100 those in humans (200–400 lg/mL). As
described previously, the serum levels of hTTR homotetramers
were much lower than expected because of the instability of hTTR
tetramers in mice [17]. Similarly, serum hRBP4 levels in our
humanized mice were about 1/100 those in humans (20–60 lg/
mL). Consequently, the hTTR:hRBP4 ratio in our humanized mice
was about 10:1, consistent with that in humans. As expected, the
serum levels of hMet30 TTR tetramers in hMet30:hRBP4 mice were
about 7 times lower than those of hVal30 TTR tetramers in
hVal30:hRBP4 mice, even though hepatic mRNA expression levels
were similar in the two strains. These ﬁndings clearly suggest that
hMet30 tetramers were much more unstable than were hVal30
tetramers in serum. Therefore, our double-humanized mice may
be an effective model for evaluating the stabilizing effects of small
molecules for hTTR tetramers.
Numerous small molecules have been discovered to impose
kinetic stabilization on the TTR native state [22–31]. Many of these
kinetic stabilizers of TTR are derivatives of non-steroidal anti-in-
ﬂammatory drugs with anti-cyclooxygenase activity. Accordingly,
these inhibitors are associated with various adverse side effects
[32–35]. Conversely, the anti-COX activity of ﬂurbiprofen was
removed by modiﬁcation at the alpha position, leading to the pro-
duction of CHF5074 [36]. Treatment with CHF5074 (375 ppm in
the diet) attenuated brain b-amyloid pathology and learning–
memory deﬁcits in a transgenic mouse model of Alzheimer disease
[13–15]. In accordance with these results, serum hVal30 and
hMet30 levels were increased about 1.5 times in hVal30:hRBP4
or approximately 5 times in hMet30:hRBP4 mice after treatment
with CHF5074 (375 ppm in the diet). These increases were due to
the CHF5074-associated stabilization of TTR tetramers, as demon-
strated by the data from the pH and urea denaturation assays.
Previous analysis of the crystal structures of CHF5074 and TTR
tetramers revealed that CHF5074 binds to the T4-binding sites of
TTR and inhibits TTR amyloidosis in vitro [16]. Our computer
simulation analysis conﬁrmed that CHF5074 binds to the T4 sites
of TTR tetramer. Interestingly, the binding afﬁnity of CHF5074 for
hVal30 was much higher than that of diﬂunisal, but CHF5074
and diﬂunisal had similar afﬁnities for hMet30. Given that most
patients with familial amyloidotic neuropathy are heterozygous
for the condition, having TTR heterotetramer composed of both
hVal30 and hMet30 monomers, the stabilizing activity of
CHF5074 may be more potent than that of diﬂunisal in clinical
applications.Liver transplantation does not ameliorate deposition of TTR in
the eye and central nervous system [37], owing to TTR synthesis
by the retinal pigment epithelium and choroid plexus. Because
CHF5074 efﬁciently crosses the blood–brain barrier [12,13,15], this
compound may be effective against amyloidosis in the eye and
central nervous system.
In conclusion, CHF5074 is a promising candidate for the treat-
ment of familial amyloid polyneuropathy owing to its stabilization
of hTTR tetramers and its lack of toxic effects.Conﬂict of interest statement
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